MEDICINE • IMMUNOTHERAPY • PHASE 3 HUMAN EVIDENCE • OCT 25, 2026
New Immunotherapy Combination Extends Survival in Aggressive Lung Cancer
Evidence status: Randomized Phase 3 trial demonstrating improved overall survival in a defined cancer population. This is disease-specific life extension, not generalized reversal of aging.
The study
DeLLphi-305 randomized 563 people with extensive-stage small-cell lung cancer whose disease had not progressed after initial durvalumab, platinum chemotherapy and etoposide. Participants received maintenance durvalumab alone or durvalumab combined with tarlatamab, a DLL3-targeted T-cell engager.
Results
| Outcome | Tarlatamab + durvalumab | Durvalumab alone |
|---|---|---|
| Median overall survival from maintenance randomization | 21.1 months | 12.7 months |
| Estimated alive at 12 months | 79% | 53% |
| Median progression-free survival | 7.4 months | 1.9 months |
The overall-survival hazard ratio was 0.42 (95% CI 0.32–0.54; p<0.001), corresponding to a 58% relative reduction in the instantaneous hazard of death during follow-up—not a guarantee that any individual patient's risk falls by exactly 58%. The median survival difference was 8.4 months. Results came from a planned interim analysis, with approximately 16 months median overall-survival follow-up.
How does it work?
Tarlatamab is a bispecific antibody that brings CD3-bearing T cells into contact with tumor cells expressing DLL3. Durvalumab blocks PD-L1, reducing an immune-inhibitory signal. Together they aim to enhance anti-tumor immune activity.
Safety and limits
Grade 3 or 4 treatment-related adverse events were reported in 20.9% of patients receiving the combination and 10.8% receiving durvalumab alone. Cytokine-release syndrome is an important recognized risk of tarlatamab and requires appropriate clinical monitoring. The combination as first-line maintenance treatment was investigational at publication; approval for other uses of a component does not imply approval of this regimen. Longer follow-up will clarify durability and late risks.
What it means for healthspan
Unlike biological-age clock changes, the primary outcome here is actual survival. That makes this a significant therapeutic advance for eligible people with an aggressive malignancy. It does not show that healthy people age more slowly, that the immune system is broadly rejuvenated, or that a general longevity treatment has been discovered.
Sources
New England Journal of Medicine: DeLLphi-305 clinical trial report
Dana-Farber Cancer Institute: trial explanation (October 24, 2026)
Detailed sponsor-reported outcomes and safety tables (October 24, 2026)
For education only, not individualized medical advice. Published October 25, 2026.